- Case report
- Open Access
- Open Peer Review
Acquired hemophagocytic syndrome related to parainfluenza virus infection: case report
© Beffermann et al.; licensee BioMed Central. 2015
- Received: 9 November 2014
- Accepted: 20 February 2015
- Published: 8 April 2015
We present the case of a patient with acquired hemophagocytic syndrome secondary to parainfluenza virus infection, a complication that has not, to the best of our knowledge, been previously reported.
A 33-year-old Chilean man with fever secondary to parainfluenza 2 virus infection developed progressive cholestasis, hepatosplenomegaly, cytopenia and an increased ferritin level (>2000IU/L). A bone marrow analysis showed hemophagocytosis. Our patient received HLH-94 chemotherapy, and he achieved complete and sustained remission after a two-year follow-up, without the need for hematopoietic stem cell transplantation.
Hemophagocytic syndrome is a severe disease with high mortality. A high index of suspicion is essential to improve survival. A viral etiology is frequent and although Epstein-Barr virus is the most frequently associated, other viruses like parainfluenza can cause this disease.
- Hemophagocytic syndrome
- Parainfluenza virus
Acquired causes of hemophagocytic syndrome
Viral: Epstein-Barr, cytomegalovirus, herpes simplex, varicella, human immunodeficiency virus
Common variable immunodeficiency
Bacterial: Brucellosis, Tuberculosis
Antiretroviral T therapy
Drug reaction (or rash) with eosinophilia and systemic symptoms syndrome
Diagnostic criteria for hemophagocytic syndrome according to trial HLH-2004
Confirmed molecular disease:
PRF1 mutation, UNC13D, Munc 18-2, Rab27a, STX11, SH2D1A, BIRC4
Five of eight clinical and laboratory criteria:
3. Cytopenia affecting two or more cell lines:
• Hemoglobin <9g/dL
• Platelets <100,000/mL
• Neutrophils <1000/mL
4. Hypertriglyceridemia (fasting triglycerides >265mg/dL or 3mMol/L) and or hypofibrinogenemia (<150mg/dL)
5. Hemophagocytosis in bone marrow, spleen, liver, lymph node, skin
6. Decreased or absent natural killer cell activity
7. Ferritin >500ng/mLa
8. Soluble CD25 >2400U/mL
A 33-year-old Chilean man presented to our emergency room with a fever of one week’s duration associated with abdominal and back pain. On admission, fever was confirmed (39°C) and findings from a physical examination were normal. Our patient’s daughters had also had a fever with virus-like upper respiratory symptoms one week prior to the onset of our patient’s symptoms.
Initial laboratory tests showed elevated C-reactive protein and a normal cell blood count. Blood and urine cultures showed no infection. There was no alteration in his biochemical serum values. A chest radiography and abdominopelvic computed tomography showed no anomalies. A diagnosis of fever of unknown origin was made and empirical antibiotic therapy (ceftriaxone) was started. Respiratory and enteric viral polymerase chain reaction testing was performed, showing parainfluenza virus-2.
Patient’s laboratory findings
Day of follow-up
Laboratory parameter (normal value)
White blood cell count (4500 to 11,000/μL)
Hemoglobin (12 to 16gr %)
Platelets (140,000 to 400,000/μL)
Alanine transaminase (10 to 40IU)
Aspartate transaminase (10 to 55IU)
Gamma-glutamyltransferase (4 to 50IU)
Ferritin (20 to 390IU/L)
Lactate dehydrogenase (135 to 225IU)
Because of our patient’s rapid clinical progression with diagnostic elements compatible with HS, specific therapy was initiated.
On the 11th day of our patient’s admission, chemotherapy protocol HLH-94 was initiated with intravenous etoposide (150mg/m2 twice weekly for two weeks, then once weekly for six weeks), intravenous dexamethasone (10mg/m2 daily during weeks one and two, then 5mg/m2 daily during weeks three and four, 2.5mg/m2 daily during weeks five and six, and finally 1.25mg/m2 daily during weeks seven and eight), cyclosporine in doses needed to reach plasmatic levels between 200 and 400μg/dL, and standard prophylactic anti-fungal and antibiotic therapy. A couple of days after the initiation of chemotherapy, our patient showed an acute impairment of consciousness and respiratory failure without coagulopathy, requiring mechanical ventilation. Brain magnetic resonance imaging showed a 45cm3 left thalamic hematoma, with insular cortex involvement, mass effect and minimal midline displacement. After his respiratory failure was resolved, global aphasia, right-sided hemiparesis, and swallowing dysfunction were evident. Our patient received physiotherapy and speech therapy, resulting in progressive improvement.
During the second week of chemotherapy, our patient had neutropenic fever, which was treated with broad spectrum antibiotics (cefepime plus vancomycin). Tests revealed a non-fungal lung infection, with a negative etiologic study. Complete resolution was achieved before our patient was discharged.
After initiating the HLH-94 protocol, our patient’s ferritin levels declined gradually. Our patient’s brother was studied for the possibility of an allogeneic hematopoietic stem cell transplantation (HSCT), resulting in human leukocyte antigen full match compatibility. During hospitalization, our patient received two weeks of etoposide and dexamethasone and was discharged to complete outpatient chemotherapy. Cyclosporine was gradually decreased until suspension one year after diagnosis. After two years of follow-up, our patient continues to be in complete remission without the need of a HSCT, with a good quality of life and ferritin levels in normal ranges.
We describe the case of a patient with a common respiratory infection that progressed into acquired HS. Because it was highly unlikely that our patient had an autosomal recessive disorder, which, according to available evidence, would have presented earlier in life (childhood or adolescence), and because laboratory tests ruled out any other cause of macrophage hyperactivation, we believe that the presence of this virus had a pathogenic role in triggering the HS.
Regardless of the cause or trigger, treatment of HS should be based on urgent commencement of chemotherapy and HSCT if necessary. The HLH-94 protocol has achieved an overall survival rate of 55% at 3.1 years in a pediatric population [14,15], and is particularly beneficial in the subgroup of patients without autosomal recessive abnormality of the genes responsible for the disease (heterozygous or homozygous) and with a clear association with viral disease, as in our case. HSCT is mainly performed in patients who are refractory to treatment and in primary forms of the disease, especially in children.
Our patient’s response to HLH-94 was good, with normalization of his ferritin levels and blood cell counts, significant improvement in his neurological deficit, and with no clinical or laboratory evidence of new macrophage hyperactivation. Intrathecal methotrexate was not used because our patient did not present with neurological compromise attributable to macrophage hyperactivation. Our patient’s intracerebral hemorrhage, although concomitant with the clinical course, apparently had no relationship to his HS, especially considering that this syndrome manifests in the central nervous system primarily as encephalitis, seizures or lymphocytic meningitis. However, the association could not be ruled out with certainty.
HS is a very rare condition that requires a high index of suspicion, because there is a 90% early mortality without specific treatment. Hospitalists should have early suspicion of this lethal disease and achieve an early diagnosis, especially in patients with acquired disease with possible autoimmune or viral causes. Management should be in the hands of a specialist hematological team, with advanced life support in severe cases of HS. In our case, our patient progressed satisfactorily because of a rapid initiation of chemotherapy, optimal management of vital support, and appropriate treatment of his complications. HLH-94 protocol remains the mainstay of treatment [14,15] and has remarkably improved overall survival in acquired HS. In patients with hereditary or congenital forms of the disease, HSCT must be a priority.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Jordan M, Allen C, Weitzman S, Filipovich A, McClain K. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041–52.View ArticlePubMedPubMed CentralGoogle Scholar
- Filipovich A. Hemophagocytic lymphohistiocytosis and other hemophagocytic syndromes. Immunol Allergy Clin N Am. 2008;28:293–313.View ArticleGoogle Scholar
- Henter J, Elinder G, Söder O, Ost A. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand. 1991;80(4):428–35.View ArticlePubMedGoogle Scholar
- Reiner A, Spivak J. Hematophagic histiocytosis. A report of 23 new patients and a review of the literature. Medicine (Baltimore). 1988;67(6):369–88.View ArticlePubMedGoogle Scholar
- Okuda T, Sakamoto S, Deguchi T, Misawa S, Kashima K, Yoshihara T, et al. Hemophagocytic syndrome associated with aggressive natural killer cell leukemia. Am J Hematol. 1991;38(4):321–3.View ArticlePubMedGoogle Scholar
- Fox C, Shannon-Lowe C, Gothard P, Kishore B, Neilson J, O’Connor N, et al. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults characterized by high viral genome load within circulating natural killer cells. Clin Infect Dis. 2010;51(1):66–9.View ArticlePubMedGoogle Scholar
- Shimizu Y, Tanae K, Takahashi N, Kohri M, Arai E, Bessho M, et al. Primary cutaneous anaplastic large-cell lymphoma presenting with hemophagocytic syndrome: a case report and review of the literature. Leuk Res. 2010;34(2):263–6.View ArticlePubMedGoogle Scholar
- Karras A, Thervet E, Legendre C. Groupe Coopératif de transplantation d’Ile de France. Hemophagocytic syndrome in renal transplant recipients: report of 17 cases and review of literature. Transplantation. 2004;77(2):238–43.View ArticlePubMedGoogle Scholar
- Lladó L, Figueras J, Comí S, Torras J, Serrano T, Castellote J, et al. Haemophagocytic syndrome after liver transplantation in adults. Transpl Int. 2004;17(4):221–3.View ArticlePubMedGoogle Scholar
- George TI, Jeng M, Berquist W, Cherry AM, Link MP, Arber DA. Epstein-Barr virus-associated peripheral T-cell lymphoma and hemophagocytic syndrome arising after liver transplantation: case report and review of the literature. Pediatr Blood Cancer. 2005;44(3):270–6.View ArticlePubMedGoogle Scholar
- Chen T, Wong W, Chiou T. Hemophagocytic syndrome: an unusual manifestation of acute human immunodeficiency virus infection. Int J Hematol. 2003;78(5):450–2.View ArticlePubMedGoogle Scholar
- Fardet L, Blum L, Kerob D, Agbalika F, Galicier L, Dupuy A, et al. Human herpes virus 8-associated hemophagocytic lymphohistiocytosis in human immunodeficiency virus-infected patients. Clin Infect Dis. 2003;37(2):285–91.View ArticlePubMedGoogle Scholar
- Grossman J, Radhi M, Schauer D, Gerday E, Grose C, Goldman F. Development of hemophagocytic lymphohistiocytosis in triplets infected with HHV-8. Blood. 2005;106(4):1203–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Henter J, Samuelsson-Horne A, Aricò M, Egeler R, Elinder G, Filipovich A, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367–73.View ArticlePubMedGoogle Scholar
- Trottestam H, Horne A, Aricò M, Egeler R, Filipovich A, Gadner H, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118(17):4577–84.View ArticlePubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.